Compare JXN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JXN | ERAS |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | United States |
| Employees | N/A | 103 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.3B |
| IPO Year | 2020 | 2021 |
| Metric | JXN | ERAS |
|---|---|---|
| Price | $134.25 | $18.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $112.40 | $14.25 |
| AVG Volume (30 Days) | 543.8K | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $6,683,000,000.00 | N/A |
| Revenue This Year | $15.15 | N/A |
| Revenue Next Year | $3.44 | N/A |
| P/E Ratio | $44.79 | ★ N/A |
| Revenue Growth | ★ 104.31 | N/A |
| 52 Week Low | $89.67 | $1.33 |
| 52 Week High | $137.99 | $24.28 |
| Indicator | JXN | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 53.57 |
| Support Level | $128.97 | $17.36 |
| Resistance Level | $137.55 | $18.71 |
| Average True Range (ATR) | 3.08 | 1.16 |
| MACD | -0.43 | 0.06 |
| Stochastic Oscillator | 66.24 | 43.08 |
Jackson Financial Inc helps Americans grow and protect their retirement savings and income to enable them to pursue financial freedom for life. Its retail product offerings are comprised of annuities, designed to help retail investors save for and live in retirement. Its diverse suite of annuities includes a variable, fixed index, and fixed annuities. The company manages its business through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks and Corporate and Other segments. The company generates the majority of its revenue from the Retail Annuities segment, which offers a variety of retirement income and savings products of variable annuities, registered index-linked annuities ("RILA"), fixed index annuities, fixed annuities, and payout annuities.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.